《Table 2 Representative indices predicting≥F3 fibrosis in non-alcoholic fatty liver disease patients

  提示：宽带有限、当前游客访问压缩模式

本系列图表出处文件名：随高清版一同展现

《"Current status, problems, and perspectives of non-alcoholic fatty liver disease research"》

1. 获取 高清版本忘记账户？点击这里登录

1. 下载图表忘记账户？点击这里登录

BMI:Body mass index；IFG:Impaired fasting glucose；DM:Diabetes mellitus；AST:Aspartate aminotransferase；ALT:Alanine aminotransferase；PLT:Platelet count；Alb:Albumin；4C7S:Type 4 collagen 7S；P-III-P:Procollagen type III amino-terminal peptide；TIMP-1:Tissue inhi

Novel agents under clinical trials:Several promising agents undergoing clinical trials are listed in Table 3.Among them，obeticholic acid，elafibranor，selonsertib，and cenicriviroc are now in phase III trials[83].It is noteworthy that these trials evaluate not only histological improvement of NASH，but also the benefit of long-term outcome for NASH patients，such as prevention of progression into cirrhosis，hepatic decompensation，and death.